Wednesday, July 8, 2026

pharma · Unstable Angina Pectoris · Gastric Carcinoma · COLL

COLLEGIUM PHARMACEUTICAL

Collegium Pharmaceutical is a pharma organization headquartered in Stoughton, USA. It trades on NYSE under ticker COLL. Primary therapeutic focus areas include Unstable Angina Pectoris, Gastric Carcinoma, aspirin-exacerb

100 Technology Center Dr, Stoughton, Massachusetts 02072, US HQ
617 Employees
Public company Type
COLL · NYSE Ticker
Company details
Status
Public
HQ
100 Technology Center Dr, Stoughton, Massachusetts 02072, US
Employees
617
Programs
29
Drugs
48
Patents
28
Clinical program

Crushed ticagrelor followed by morphine

Approved · small molecule · Unstable Angina Pectoris

Crushed ticagrelor followed by morphine for Unstable Angina Pectoris is a Approved program (small_molecule) at COLLEGIUM PHARMACEUTICAL, INC with 2 ClinicalTrials.gov record(s).

← All COLLEGIUM PHARMACEUTICAL, INC projects Approved small molecule completed

Internal code CMUMK202F

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
COLLEGIUM PHARMACEUTICAL, INC
Phase
Approved
Modality
small_molecule
Indication
Unstable Angina Pectoris
Status
completed
Trials
2